• Celldex published topline Phase 2 results for barzolvolimab in prurigo nodularis, using a June 25, 2026 data cutoff.
• The trial missed the Week 12 primary endpoint on itch response (p=0.868 for 150 mg; p=0.428 for 300 mg).
• Key secondary endpoints also missed, including IGA-CNPG-S response (p=0.317; p=0.748) and combined itch-plus-IGA response (p=0.411; p=0.565).
• The program will be discontinued in prurigo nodularis despite profound tryptase reductions indicating systemic mast cell depletion.
• Phase 3 chronic spontaneous urticaria topline data remain expected in September/October.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.